Literature DB >> 24903614

Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.

A V Marzano1, D Fanoni, E Antiga, P Quaglino, M Caproni, C Crosti, P L Meroni, M Cugno.   

Abstract

Pyoderma gangrenosum (PG) and Sweet's syndrome (SS) are two inflammatory skin diseases presenting with painful ulcers and erythematous plaques, respectively; both disorders have a debilitating clinical behaviour and PG is potentially life-threatening. Recently, PG and SS have been included among the autoinflammatory diseases, which are characterized by recurrent episodes of sterile inflammation, without circulating autoantibodies and autoreactive T cells. However, an autoinflammatory pattern clearly supporting this inclusion has never been demonstrated. We studied 16 patients with PG, six with SS and six controls, evaluating, using a sandwich-based protein antibody array method, the expression profile of inflammatory effector molecules in PG, SS and normal skin. The expressions of interleukin (IL)-1 beta and its receptor I were significantly higher in PG (P = 0·0001 for both) and SS (P = 0·004-0·040) than in controls. In PG, chemokines such as IL-8 (P = 0·0001), chemokine (C-X-C motif) ligand (CXCL) 1/2/3 (P = 0·002), CXCL 16 (P = 0·003) and regulated upon activation normal T cell expressed and secreted (RANTES) (P = 0·005) were over-expressed. In SS, IL-8 (P = 0·018), CXCL 1/2/3 (P = 0·006) and CXCL 16 (P = 0·036) but not RANTES were over-expressed, suggesting that chemokine-mediated signals are lower than in PG. Fas/Fas ligand and CD40/CD40 ligand systems were over-expressed in PG (P = 0·0001 for Fas, P = 0·009 for Fas ligand, P = 0·012 for CD40, P = 0·0001 for CD40 ligand), contributing to tissue damage and inflammation, while their role seems to be less significant in SS. Over-expression of cytokines/chemokines and molecules amplifying the inflammatory network supports the view that PG and SS are autoinflammatory diseases. The differences in expression profile of inflammatory effectors between these two disorders may explain the stronger local aggressiveness in PG than SS.
© 2014 British Society for Immunology.

Entities:  

Keywords:  Sweet's syndrome; autoinflammation; chemokines; cytokines; pyoderma gangrenosum

Mesh:

Substances:

Year:  2014        PMID: 24903614      PMCID: PMC4360193          DOI: 10.1111/cei.12394

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Pyoderma gangrenosum: study of 21 patients and proposal of a 'clinicotherapeutic' classification.

Authors:  Angelo Valerio Marzano; Valentina Trevisan; Riccardo Lazzari; Carlo Crosti
Journal:  J Dermatolog Treat       Date:  2010-07-28       Impact factor: 3.359

Review 2.  A clinical perspective of IL-1β as the gatekeeper of inflammation.

Authors:  Charles A Dinarello
Journal:  Eur J Immunol       Date:  2011-05       Impact factor: 5.532

Review 3.  Genetics of monogenic autoinflammatory diseases: past successes, future challenges.

Authors:  Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Rev Rheumatol       Date:  2011-07-05       Impact factor: 20.543

Review 4.  Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma.

Authors:  Rachel L Kyllo; Mary Kendall Parker; Ilana Rosman; Amy C Musiek
Journal:  J Am Acad Dermatol       Date:  2014-04       Impact factor: 11.527

5.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.

Authors:  Emmanuella Guenova; Anna Teske; Birgit Fehrenbacher; Sebastian Hoerber; Annette Adamczyk; Martin Schaller; Wolfram Hoetzenecker; Tilo Biedermann
Journal:  Arch Dermatol       Date:  2011-06-16

6.  Alteration in the gene encoding protein tyrosine phosphatase nonreceptor type 6 (PTPN6/SHP1) may contribute to neutrophilic dermatoses.

Authors:  Andrew B Nesterovitch; Zsuzsa Gyorfy; Mark D Hoffman; Ellen C Moore; Nada Elbuluk; Beata Tryniszewska; Tibor A Rauch; Melinda Simon; Sewon Kang; Gary J Fisher; Katalin Mikecz; Michael D Tharp; Tibor T Glant
Journal:  Am J Pathol       Date:  2011-03-04       Impact factor: 4.307

Review 7.  Siglecs and immune regulation.

Authors:  Shiv Pillai; Ilka Arun Netravali; Annaiah Cariappa; Hamid Mattoo
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

Review 8.  The etiology of paraneoplastic autoimmunity.

Authors:  Emanual Maverakis; Heidi Goodarzi; Lisa N Wehrli; Yoko Ono; Miki Shirakawa Garcia
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

Review 9.  Etiology and management of pyoderma gangrenosum: a comprehensive review.

Authors:  Iris Ahronowitz; Joanna Harp; Kanade Shinkai
Journal:  Am J Clin Dermatol       Date:  2012-06-01       Impact factor: 7.403

10.  Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.

Authors:  A V Marzano; M Cugno; V Trevisan; D Fanoni; L Venegoni; E Berti; C Crosti
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

View more
  51 in total

Review 1.  Neutrophilic dermatoses and autoinflammatory diseases with skin involvement--innate immune disorders.

Authors:  Alexander A Navarini; Takashi K Satoh; Lars E French
Journal:  Semin Immunopathol       Date:  2015-11-30       Impact factor: 9.623

Review 2.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

3.  Refractory skin lesion, hypertension, and acute kidney injury in a young boy: Answers.

Authors:  Valeriya M Feygina; Thomas F Hahn; Dianne G Muchant
Journal:  Pediatr Nephrol       Date:  2017-01-18       Impact factor: 3.714

4.  A sweet fever.

Authors:  Silvia Tiraboschi; Angelo Valerio Marzano; Rosa Lombardi; Giovanni Genovese; Giovanni Boccoli; Silvia Fargion; Anna Ludovica Fracanzani
Journal:  Intern Emerg Med       Date:  2018-11-08       Impact factor: 3.397

Review 5.  [Pyoderma gangrenosum].

Authors:  K Herberger
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

6.  Corrigendum.

Authors: 
Journal:  Clin Exp Immunol       Date:  2015-07       Impact factor: 4.330

7.  T helper type 1-related molecules as well as interleukin-15 are hyperexpressed in the skin lesions of patients with pyoderma gangrenosum.

Authors:  E Antiga; R Maglie; W Volpi; B Bianchi; E Berti; A V Marzano; M Caproni
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

8.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 9.  Pyoderma gangrenosum-like ulcerations in granulomatosis with polyangiitis: two cases and literature review.

Authors:  Giovanni Genovese; Simona Tavecchio; Emilio Berti; Franco Rongioletti; Angelo Valerio Marzano
Journal:  Rheumatol Int       Date:  2018-05-02       Impact factor: 2.631

Review 10.  Pyoderma gangrenosum after orthopaedic or traumatologic surgery: a systematic revue of the literature.

Authors:  Stephan Ebrad; Mathieu Severyns; Ahmed Benzakour; Benoit Roze; Christian Derancourt; Guillaume-Anthony Odri; Jean-Louis Rouvillain
Journal:  Int Orthop       Date:  2017-11-08       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.